Immunology Collaboration and Licensing Deals 2018-2026
919 immunology partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic indication and target analysis | Contract intelligence
Immunology Collaboration and Licensing Deals 2018–2026
Understand the immunology partnering landscape using intelligence from real-world collaboration and licensing deals.
Immunology Collaboration and Licensing Deals 2018–2026 provides comprehensive intelligence on 919 partnering deals involving immunology assets, technologies and development programs.
Immunology is a broad and highly active area of life sciences partnering, encompassing multiple disease areas, mechanisms of action, therapeutic technologies and stages of development. Deal structures reflect both the scientific diversity of the field and the different strategies companies use to access, develop and commercialize innovation.
The report brings this activity together in one resource, enabling users to understand who is partnering, which immunology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in immunology partnering.
Understand the immunology partnering landscape
The report analyzes immunology dealmaking from 2018 to 2026, including:
-
Trends in immunology partnering by year
-
Deal activity by deal type
-
Industry sector
-
Stage of development at the time of partnering
-
Technology type
-
Therapeutic indication
-
Most active immunology dealmakers
-
Leading deals by disclosed value
-
How immunology partnering activity is evolving
This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
Benchmark immunology deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.
The report provides dedicated analysis of disclosed financial terms, including:
-
Headline deal values
-
Upfront payments
-
Milestone payments
-
Royalty rates
Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading immunology dealmakers and prospective partners
The report identifies the most active companies in immunology partnering and provides transaction histories that enable users to investigate their previous activity.
This can help users identify:
-
Companies actively seeking immunology opportunities
-
Prospective licensing and collaboration partners
-
Organizations repeatedly partnering in relevant disease areas
-
Companies active at relevant stages of development
-
Dealmakers demonstrating interest in particular mechanisms, technologies or therapeutic approaches
-
Competitors pursuing related external innovation strategies
For companies seeking to partner an immunology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
Compare partnering activity across immunology indications and targets
Immunology encompasses a wide range of therapeutic indications and biological targets with differing scientific, clinical and commercial dynamics.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad immunology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how immunology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.
Depending on the transaction and available disclosure, users can investigate areas including:
-
Rights granted and retained
-
Research and development responsibilities
-
Licensing rights
-
Exclusivity
-
Geographic rights
-
Intellectual property
-
Development and regulatory obligations
-
Manufacturing and supply responsibilities
-
Commercialization rights
-
Financial consideration
-
Milestones and royalties
-
Governance
-
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for an immunology partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected immunology transactions.
These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
-
Scope of rights
-
Development obligations
-
Intellectual property
-
Exclusivity
-
Financial terms
-
Milestone triggers
-
Royalty provisions
-
Commercialization rights
-
Termination and other negotiated provisions
For teams preparing or negotiating an immunology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive immunology deal directory
The report includes a comprehensive directory of immunology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.
Deals can be reviewed by:
-
Company
-
Technology type
-
Therapeutic indication or target
-
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable immunology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking immunology opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable immunology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building immunology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide immunology intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying immunology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.
Key Benefits
✔ Benchmark against 919 immunology partnering deals – Access a substantial body of real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.
✔ Benchmark immunology deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.
✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in immunology assets, technologies, therapeutic indications, targets and relevant stages of development.
✔ Compare activity across the immunology landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.
✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, technologies, development stages and partnering structures.
✔ Understand how immunology deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.
✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.
✔ Apply the intelligence to your own immunology opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in immunology dealmaking
2.1. Introduction
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Immunology partnering by technology type
2.7. Immunology partnering by therapeutic indication
Chapter 3 – Financial deal terms for immunology partnering
3.1. Introduction
3.2. Disclosed financials terms for immunology partnering
3.3. Immunology partnering headline values
3.4. Immunology deal upfront payments
3.5. Immunology deal milestone payments
3.6. Immunology royalty rates
Chapter 4 – Leading immunology deals and dealmakers
4.1. Introduction
4.2. Most active in immunology partnering
4.3. List of most active dealmakers in immunology
4.4. Top immunology deals by value
Chapter 5 – Immunology contract document directory
5.1. Introduction
5.2. Immunology partnering deals where contract document available
Chapter 6 – Immunology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by immunology therapeutic target
Deal directory
Deal directory – Immunology deals by company A-Z
Deal directory – Immunology deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Immunology partnering since 2018
Figure 2: Immunology partnering by deal type since 2018
Figure 3: Immunology partnering by industry sector since 2018
Figure 4: Immunology partnering by stage of development since 2018
Figure 5: Immunology partnering by technology type since 2018
Figure 6: Immunology partnering by indication since 2018
Figure 7: Immunology deals with a headline value
Figure 8: Immunology deals with upfront payment values
Figure 9: Immunology deals with milestone payment
Figure 10: Immunology deals with royalty rates
Figure 11: Active immunology dealmaking activity since 2018
Figure 12: Top immunology deals by value since 2018
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by Evalon.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.